Please login to the form below

Not currently logged in
Email:
Password:

Teva takes majority stake in Taiyo

Israel's Teva is to take 57 per cent share in Japanese generic medicines manufacturer Taiyo

Teva Pharmaceutical Industries has signed a definite agreement to acquire 57 per cent of the share held in privately-owned Taiyo Pharmaceutical Industry Company for $460m in cash.

Shlomo Yanai, Teva president and chief executive, said: "This acquisition will enable Teva to deliver on our strategic objective of becoming a leading player in the fast-growing Japanese generics market. In fact, we now expect to reach our 2015 target of $1bn sales in Japan ahead of schedule."

The deal is subject to the approval of Taiyo's shareholder meeting, but it is expected to be complete by the end of September.

Meanwhile Teva has won the largest share of a new drug delivery tender by Germany's largest healthcare fund Allgemeinen Orstskrankassen. It secured 152 two-year supply contracts, 27 per cent of the contracts in the tender. The contracts come into effect on June 1.

16th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics